US Stock MarketDetailed Quotes

RVMD Revolution Medicines

Watchlist
  • 44.060
  • +0.770+1.78%
Close Dec 20 16:00 ET
  • 43.800
  • -0.260-0.59%
Post 20:01 ET
8.14BMarket Cap-12.04P/E (TTM)

Revolution Medicines Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Revolution Medicines Q3 2024 Earnings Date

Currency：USDNov 6, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
346.15K
0
-346.15K
Miss Est.
--
--
-100.00%
EPS
-0.90
-0.94
-0.04
Miss Est.
+9.38%
+5.05%
-4.79%
Analyst Rating
Strong Buy

Dec 22, 2024

Revolution Medicines Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 9 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 346.150K--
Nov 6, 20242024/Q30.000 / 346.150K--
Aug 7, 20242024/Q20.000 / 807.690K--
May 8, 20242024/Q10.000 / 674.200K--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 346.150K--
Nov 6, 20242024/Q30.000 / 346.150K--
Aug 7, 20242024/Q20.000 / 807.690K--
May 8, 20242024/Q10.000 / 674.200K--

Unlock Free Earnings Estimates

Revolution Medicines Earnings Reports

  • 10-Q: Q3 2024 Earnings Report

    Nov 6 16:15 ET

  • 8-K: Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

    Nov 6 16:07 ET

  • 10-Q: Q2 2024 Earnings Report

    Aug 7 16:18 ET

  • 8-K: Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

    Aug 7 16:11 ET

    • Read more

    Trending US Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Ermenegildo Zegna NV
    ZGN
    +6.16%
    DexCom
    DXCM
    +5.57%
    New Fortress Energy
    NFE
    +5.37%
    Workday
    WDAY
    +2.33%
    eBay
    EBAY
    +1.66%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Dec 22, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data